The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,566.00
Bid: 12,566.00
Ask: 12,570.00
Change: 50.00 (0.40%)
Spread: 4.00 (0.032%)
Open: 12,566.00
High: 12,632.00
Low: 12,512.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks down as BoE confirms end to bond-buying

Wed, 12th Oct 2022 17:00

(Alliance News) - Stock prices in London closed in the red on Wednesday, as discouraging economic data and mixed signals from the UK's central bank weighed on investor sentiment.

The FTSE 100 index closed down 59.08 points, 0.9%, at 6,826.15. The FTSE 250 ended down 292.90 points, 1.7%, at 16,611.16, and the AIM All-Share closed down 11.43 points, 1.5%, at 776.27.

The Cboe UK 100 ended down 0.9% at 681.94, the Cboe UK 250 closed down 2.0% at 14,231.10, and the Cboe Small Companies ended down 1.7% at 12,308.79.

In European equities on Wednesday, the CAC 40 in Paris ended down 0.3%, while the DAX 40 in Frankfurt ended down 0.4%.

The UK economy faced yet more turmoil, with economic data painting a fairly gloomy picture.

The nation's trade deficit widened, its industrial production shrunk and its gross domestic product also weakened.

Figures showed the UK economy shrank by 0.3% in August from July, following a downwardly revised 0.1% climb in July from June. Month-on-month growth in July was initially forecast at 0.2%.

August's gross domestic product was expected to have remained unchanged from July.

"While July's economic health was bolstered by a number of sporting events that got people out and about, August was coloured with caution. Households were terrified about what the winter ahead had in store, as they read headlines predicting horrific energy bills, and witnessed first-hand as inflation squeezed their spending power," said AJ Bell's Danni Hewson.

"Rising prices, falling confidence and cooling temperatures seem to be the perfect recipe for recession and there's every indication that in September the economy will have followed August's path, helped along by a bank holiday detour."

The pound was quoted at USD1.1066 at the London equities close Wednesday, down compared to USD1.1097 at the close on Tuesday. It had hit a two-week low of USD1.0924 earlier in the day.

Sterling saw a turbulent day of trading, following some mixed messages from the Bank of England.

BoE Governor Andrew Bailey confirmed late Tuesday that the emergency interventions would halt this week, but on Wednesday morning, the Financial Times reported the bank had privately signalled it was considering extending the bond-buying programme beyond the Friday deadline.

Later in the day, the bank confirmed the scheme would end on Friday.

"The Bank of England's messaging to the market over the last 24-hours has been conflicted and confused, causing unnecessary gyrations to the pound and adding to the sense of instability in the markets," interactive investor's Victoria Scholar commented.

The euro stood at USD0.9702 at the European equities close Wednesday, down against USD0.9719 at the same time on Tuesday.

Against the yen, the dollar was trading at JPY146.90, sharply higher compared to JPY145.70 late Tuesday.

Meanwhile, producer inflation heated up in the US. Producer prices increased in September, data from the Bureau of Labor Statistics showed, reversing from August's decline and exceeding market expectations.

The producer price index increased 0.4% in September from the previous month, partially reversing declines of 0.2% in August and 0.4% in July.

Market consensus, according to FX Street, had predicted a 0.2% rise.

Investors will have a keen eye on Thursday's US consumer price inflation figures, which will be a key factor in determining the US Federal Reserve's interest rate decision next month.

Stocks in New York were higher at the London equities close, with the DJIA up 0.5%, the S&P 500 index 0.2%, and the Nasdaq Composite up 0.2%.

In the FTSE 100, AstraZeneca edged up 1.1% on "exceptional data" for its drug Ultomiris. Towards the end of this month, AZ's subsidiary Alexion Pharmaceuticals will present data showing "significant advances" for the treatment of a form of neuromyelitis.

At the other end of the index was JD Sports, which lost 9.7%. After some high-profile changes to its once controversial leadership in recent months, the athleisure retailer announced its Chief Financial Officer Neil Greenlagh will step down next year.

JD will now begin the process of recruiting his successor.

Another poor blue chip performer was Barratt Homes, falling 5.0%. The housebuilder warned private reservations are down from a year earlier, as the sector battles a tough economic climate.

"Barratt cites increased wider economic uncertainty thanks to the knock to consumers' confidence and pockets from the increased cost of living, higher interest rates and also a reduction in mortgage availability. All three factors bear the fingerprints of both the government and the Bank of England and the drop in mortgage availability is a direct result of the financial market fall-out which followed the chancellor's botched fiscal event of 23 September," said AJ Bell investment director, Russ Mould.

In a negative read-across fellow housebuilders Persimmon and Crest Nicholson lost 5.8% and 6.6% respectively

In the midcaps, Marks & Spencer lost 4.8%. In a presentation to investors, the grocer said it is accelerating a major shake-up of its stores estate, and will close 67 more shops.

M&S stressed that the previously announced closures will be more than offset by new openings as the group seeks to focus more on its grocery business and online operations.

On AIM, environmental and life science group Deepverge plunged 45%.

The Dublin-based artificial intelligence tech firm warned it may not be able to raise "sufficient equity funds" as repayments for a loan fall due.

It secured a GBP25 million loan in March, of which an initial GBP4 million was drawn. The firm stated that monthly repayments begin on Sunday, with an initial GBP500,000 due.

DeepVerge added there will be no default on the loan despite any missed payments up to November 14, assuming principal and interest payments are made following a proposed equity raise.

Brent oil was quoted at USD92.55 a barrel at the London equities close Wednesday down from USD94.62 late Tuesday. Gold was quoted at USD1,670.16 an ounce, down slightly against USD1,671.20 at the close on Tuesday.

In Thursday's UK corporate calendar, there are trading statements from budget airline easyJet, gambling firm Entain, and recruitment firm Hays.

As well as US CPI and intial jobless claims at 1330 BST, the economic calendar for Thursday has German CPI at 0700 BST, and Ireland CPI at 1100 BST. There will also be remarks from BoE Monetary Policy Committee Member Catherine Mann.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.